Citations

Clear

3314 citation(s) found for "Do, Alexander".

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, Kristin A. , Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Diver, W. Ryan , Hennis, Anselm , Nemesure, Barbara , Klein, Eric A. , Rybicki, Benjamin A. , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Stephens, Owen , Zangari, Maurizio , Hu, Jennifer J. , Nyante, Sarah J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Tomasson, Michael H. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Chiu, Brian C.‐H. , Ziv, Elad , Vij, Ravi , Bernal‐Mizrachi, Leon , Morgan, Gareth J. , Zonder, Jeffrey A. , Huff, Carol Ann , Orlowski, Robert Z. , Conti, David V. , Haiman, Christopher A. , Orlowski, Robert Z. , John, Esther M , Klein, Eric A , Nyante, Sarah , Morgan, Gareth J , Ziv, Elad , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Bernstein, Leslie , Rhee, Frits van , Olshan, Andrew F. , Zheng, Wei , Ziegler, Regina G. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Stram, Daniel O. , Lonial, Sagar , Cozen, Wendy

Mayo Clinic

Blood Advances | January 14, 2020 | Volume: 4 | Issue: 1 | Pages: 181-190

10.1182/bloodadvances.2019000491 | PMID 31935283 Get It

Abstract Persons of African ancestry (AA) have a twofold higher risk for multiple myeloma (MM) compared with persons of European ancestry (EA). Genome-wide association studies (GWASs) support a genetic contribution to MM etiology in individuals of EA. Little is known about genetic risk factors for MM in individuals of AA. We performed a meta-analysis of 2 GWASs of MM in 1813 cases and 8871 controls and conducted an admixture mapping scan to identify risk alleles. We fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. In GWAS meta-analysis, we identified 2 suggestive novel loci located at 9p24.3 and 9p13.1 at P < 1 × 10−6; however, no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. Of the 23 known EA risk variants, 20 showed directional consistency, and 9 replicated at P < .05 in AA individuals. In 8 regions, we identified markers that better capture MM risk in persons with AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95% confidence interval, 1.56-2.11) increased MM risk compared with those with average risk (25%-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P = 5.1 × 10−12). Our study shows that common genetic variation contributes to MM risk in individuals with AA.
Incidence of Complications following Volar Locking Plate Fixation of Distal Radius Fractures: An Analysis of 647 Cases
DeGeorge, Brent R. , Becker, Hillary A., Brogan, David M. , Shin, Alexander Y.

Mayo Clinic

Plastic & Reconstructive Surgery | January 13, 2020 | Volume: 145 | Issue: 4 | Pages: 969-976

10.1097/prs.0000000000006636 | PMID 32221216 Get It

Background: This study assessed the risk and factors of complications after volar locking plate fixation of distal radius fractures. Methods: A single-institution retrospective review of patients undergoing volar locking plate fixation of distal radius fractures between May of 2000 and May of 2015 was undertaken. Demographic data, major complications, minor complications, and radiographic parameters were evaluated. Results: Six hundred forty-seven distal radius fractures managed with volar plate fixation in 636 patients were reviewed. Mean follow-up was 9.1 months. Mean age was 56.5 years. Mean body mass index was 28.0, and 14.6 percent of patients had a body mass index greater than 35. Fractures were classified as Arbeitsgemeinschaft für Osteosynthesefragen class 23-C (67.2 percent), 23-A (26.6 percent), and 23-B (6.2 percent). The incidence of major and minor complications was 13.8 percent and 17.5 percent, respectively. The most common complication was transient paresthesia (9.7 percent). The incidence of tendon rupture or irritation was 0.5 percent or 2.5 percent, respectively. Hardware removal for painful/symptomatic hardware occurred in 6.2 percent at an average of 427.8 days after surgery. Major complications and minor complications were increased 2.2- and 1.9-fold, respectively, in patients with a body mass index greater than 35. Major complications were also increased 3.19 times in patients with residual intraarticular step-off. Hardware removal was 3.3 times more likely in patients with Soong grade 2 plate prominence and 2.9 times more likely in patients with a history of diabetes mellitus. Conclusions: Volar plate osteosynthesis of distal radius fractures is associated with an overall low complication rate. Patient factors, including diabetes mellitus and obesity, and intraoperative factors, including intraarticular fracture alignment and plate prominence, were associated with a higher rate of complications or revision surgery. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Secord, Angeles Alvarez , Burdett, Kirsten B. , Owzar, Kouros , Tritchler, David , Sibley, Alexander B. , Starr, Mark D. , Brady, John C. , Lankes, Heather A. , Hurwitz, Herbert I. , Mannel, Robert S., Tewari, Krishnansu S. , O’Malley, David M. , Gray, Heidi J. , Boente, Matthew, Burger, Robert A. , Birrer, Michael J. , Bell Burdett, Kirsten , Hurwitz, Herbert I , Fujiwara, Keiichi , O'Malley, David M , Liu, Yingmiao , Bakkum‐Gamez, Jamie N. , Deng, Wei, Nixon, Andrew B.

Mayo Clinic

Clinical Cancer Research | January 9, 2020 | Volume: 26 | Issue: 6 | Pages: 1288-1296

10.1158/1078-0432.ccr-19-0226 | PMID 31919136 Get It

Abstract Purpose: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses. Experimental Design: Plasma samples were analyzed via multiplex ELISA technology for seven prespecified biomarkers [IL6, Ang-2, osteopontin (OPN), stromal cell–derived factor-1 (SDF-1), VEGF-D, IL6 receptor (IL6R), and GP130]. The predictive value of each biomarker with respect to PFS and OS was assessed using a protein marker by treatment interaction term within the framework of a Cox proportional hazards model. Prognostic markers were identified using Cox models adjusted for baseline covariates. Results: Baseline samples were available from 751 patients. According to our prespecified analysis plan, IL6 was predictive of a therapeutic advantage with bevacizumab for PFS (P = 0.007) and OS (P = 0.003). IL6 and OPN were found to be negative prognostic markers for both PFS and OS (P < 0.001). Patients with high median IL6 levels (dichotomized at the median) treated with bevacizumab had longer PFS (14.2 vs. 8.7 months) and OS (39.6 vs. 33.1 months) compared with placebo. Conclusions: The inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel. Aligning with results observed in patients with renal cancer treated with antiangiogenic therapies, it appears plasma IL6 may also define those patients with EOC more or less likely to benefit from the addition of bevacizumab to standard chemotherapy.
Functional Mitral Regurgitation and Left Atrial Myopathy in Heart Failure with Preserved Ejection Fraction
Tamargo, María, Obokata, Masaru , Reddy, Yogesh N.V. , Lin, Grace , Egbe, Alexander C. , Nishimura, Rick , Obokata, Masaru , Pislaru, Sorin V. , Nishimura, Rick A. , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | January 7, 2020 | Volume: 22 | Issue: 3 | Pages: 489-498

10.1002/ejhf.1699 | PMID 31908127 Get It

ABSTRACT Aims Mild to moderate functional mitral regurgitation (MR) is common in patients with heart failure and preserved ejection fraction (HFpEF) where it is usually considered as an innocent bystander. We hypothesized that MR in HFpEF reflects greater left atrial (LA) myopathy, leading to more adverse haemodynamics and poorer exercise reserve. Methods and results Patients with HFpEF (n = 280) with and without MR underwent echocardiography, invasive haemodynamic exercise testing, and expired gas analysis. As compared to non-MR-HFpEF (n = 163), patients with MR-HFpEF (n = 117; 78 mild and 39 moderate, central jet in 90%) were older, more likely female, with lower body mass and higher prevalence of atrial fibrillation (AF). HFpEF patients with MR displayed greater LA volume, reduced LA strain and compliance, and greater mitral annular dilatation, which was strongly correlated with LA dilatation (r = 0.63, P < 0.0001) but was only weakly related to left ventricular remodelling (r = 0.37). Patients with MR-HFpEF displayed worse biventricular function, more adverse pulmonary haemodynamics, impaired pulmonary vasodilatation, blunted right ventricular reserve, and reduced cardiac output with exercise as compared to non-MR-HFpEF. Importantly, these findings were maintained after excluding patients with HFpEF and AF, suggesting a role for LA myopathy in contributing to MR in HFpEF, independent of rhythm. Conclusions Functional MR in patients with HFpEF reflects LA myopathy, even in the absence of AF, and is associated with greater haemodynamic severity of disease and poorer functional capacity. Further study is required to better define causal mechanisms and potential treatments for MR and LA dysfunction in patients with HFpEF.
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Gray, Robert J. , Chen, Alice P. , Patton, David R. , Mitchell, Edith P. , Iafrate, A. John , Sklar, Jeffrey , Harris, Lyndsay N. , Rubinstein, Larry , Routbort, Mark, Coffey, Brent , Fu, Tony, Little, Richard F. , Marinucci, Donna M. , Catalano, Robert B., Magnan, Rick, Kibbe, Warren A. , Weil, Carol J. , Tricoli, James V. , Kumar, Shaji , Lih, Chih‐Jian, McCaskill‐Stevens, Worta , Takebe, Naoko, Datta, Vivekananda, Arteaga, Carlos L. , Abrams, Jeffrey S. , Comis, Robert L., O’Dwyer, Peter J , Conley, Barbara A. , Team, for the NCI-MATCH, Gray, Robert J , Patton, David R , Flaherty, Keith T. , Li, Shuli , Hamilton, Stanley R. , Williams, P. Mickey , McShane, Lisa M. , Sims, David J, Zwiebel, James A. , Alexander, Brian M. , Schwartz, Gary K. , Meric‐Bernstam, Funda , Caimi, Paolo F. , Takebe, Naoko , O’Dwyer, Peter J. , Team, for the NCI-MATCH, Rubinstein, Larry V

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 6, 2020 | Volume: 112 | Issue: 10 | Pages: 1021-1029

10.1093/jnci/djz245 | PMID 31922567 Get It

Abstract Background The proportion of tumors of various histologies that may respond to drugs targeted to molecular alterations is unknown. NCI-MATCH, a collaboration between ECOG-ACRIN Cancer Research Group and the National Cancer Institute, was initiated to find efficacy signals by matching patients with refractory malignancies to treatment targeted to potential tumor molecular drivers regardless of cancer histology. Methods Trial development required assumptions about molecular target prevalence, accrual rates, treatment eligibility, and enrollment rates as well as consideration of logistical requirements. Central tumor profiling was performed with an investigational next-generation DNA–targeted sequencing assay of alterations in 143 genes, and protein expression of protein expression of phosphatase and tensin homolog, mutL homolog 1, mutS homolog 2, and RB transcriptional corepressor 1. Treatments were allocated with a validated computational platform (MATCHBOX). A preplanned interim analysis evaluated assumptions and feasibility in this novel trial. Results At interim analysis, accrual was robust, tumor biopsies were safe (<1% severe events), and profiling success was 87.3%. Actionable molecular alteration frequency met expectations, but assignment and enrollment lagged due to histology exclusions and mismatch of resources to demand. To address this lag, we revised estimates of mutation frequencies, increased screening sample size, added treatments, and improved assay throughput and efficiency (93.9% completion and 14-day turnaround). Conclusions The experiences in the design and implementation of the NCI-MATCH trial suggest that profiling from fresh tumor biopsies and assigning treatment can be performed efficiently in a large national network trial. The success of such trials necessitates a broad screening approach and many treatment options easily accessible to patients.
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Keung, Emily Z. , Salazar, Ruth , Rodrigues-Canales, Jaime, Bolejack, Vanessa , Tine, Brian A. Van , Schuetze, Scott M. , Attia, Steven , Riedel, Richard F. , Hu, James , Okuno, Scott H. , Priebat, Dennis A., Movva, Sujana , Davis, Lara E. , Wang, Wei‐Lien , Wargo, Jennifer A. , Tawbi, Hussein A. , Bolejack, Vanessa , Van Tine, Brian A , Schuetze, Scott M , Riedel, Richard F , Okuno, Scott , Davis, Lara E , Reed, Damon R , Reuben, Alexandre , Lazar, Alexander J , Burgess, Melissa , Parra, Edwin Roger , Reed, Damon R. , Roland, Christina Lynn , Reinke, Denise K. , Lazar, Alexander J.

Mayo Clinic

Clinical Cancer Research | January 3, 2020 | Volume: 26 | Issue: 6 | Pages: 1258-1266

10.1158/1078-0432.ccr-19-1824 | PMID 31900276 Get It

Abstract Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). We sought to determine whether we can identify immune features that correlate with clinical outcomes from tumor tissues obtained pre- and on-treatment. Patients and Methods: Pretreatment (n = 78) and 8-week on-treatment (n = 68) tumor biopsies were stained for PD-L1 and multiplex immunofluorescence panels. The density of positive cells was quantified to determine associations with anti–PD-1 response. Results: Patients that responded to pembrolizumab were more likely to have higher densities of activated T cells (CD8+ CD3+ PD-1+) and increased percentage of tumor-associated macrophages (TAM) expressing PD-L1 pre-treatment compared with non-responders. Pre-treatment tumors from responders also exhibited higher densities of effector memory cytotoxic T cells and regulatory T cells compared with non-responders. In addition, higher density of cytotoxic tumor-infiltrating T cells at baseline correlated with a better progression-free survival (PFS). Conclusions: We show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, percentage of TAMs expressing PD-L1, and other T-cell densities correlate with sarcoma response to pembrolizumab and improved PFS. Our findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti–PD-1 therapy in specific advanced sarcomas. Efforts to confirm the activity of pembrolizumab in an expansion cohort of patients with UPS/DDLPS are underway.
Identification of Coryneform Bacterial Isolates by Ribosomal DNA Sequence Analysis
Graevenitz, Alexander von, Waddington, Michael, Hopkins, Marlene K., Smith, Douglas H. , Li, Haijing , Kolbert, Christopher P., Montgomery, Stacy O., Persing, David H., Tang, Yi‐Wei

Mayo Clinic

Journal of Clinical Microbiology | December 31, 2019 | Volume: 38 | Issue: 4 | Pages: 1676-1678

10.1128/jcm.38.4.1676-1678.2000 | PMID 10747168 Get It

ABSTRACT Identification of coryneform bacteria to the species level is important in certain circumstances for differentiating contamination and/or colonization from infection, which influences decisions regarding clinical intervention. However, methods currently used in clinical microbiology laboratories for the species identification of coryneform bacteria are often inadequate. We evaluated the MicroSeq 500 16S bacterial sequencing kit (Perkin-Elmer Biosystems, Foster City, Calif.), which is designed to sequence the first 527 bp of the 16S rRNA gene for bacterial identification, by using 52 coryneform gram-positive bacilli from clinical specimens isolated from January through June 1993 at the Mayo Clinic. Compared to conventional and supplemented phenotypic methods, MicroSeq provided concordant results for identification to the genus level for all isolates. At the species level, MicroSeq provided concordant results for 27 of 42 (64.3%) Corynebacterium isolates and 5 of 6 (83.3%) Corynebacterium -related isolates, respectively. Within the Corynebacterium genus, MicroSeq gave identical species-level identifications for the clinically significant Corynebacterium diphtheriae (4 of 4) and Corynebacterium jeikeium (8 of 8), but it identified only 50.0% (15 of 30) of other species ( P < 0.01). Four isolates from the genera Arthrobacter , Brevibacterium , and Microbacterium , which could not be identified to the species level by conventional methods, were assigned a species-level identification by MicroSeq. The total elapsed time for running a MicroSeq identification was 15.5 to 18.5 h. These data demonstrate that the MicroSeq 500 16S bacterial sequencing kit provides a potentially powerful method for the definitive identification of clinical coryneform bacterium isolates.
Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate
Gandhi, Jatin , Smith, Steven C. , Paner, Gladell P. , McKenney, Jesse K. , Sekhri, Radhika , Osunkoya, Adeboye O. , Baras, Alexander S. , Cheville, John C. , Jiménez, Rafael E. , Trpkov, Kiril , Colecchia, Maurizio , Ro, Jae Y. , Montironi, Rodolfo , Hes, Ondřej , Hirsch, Michelle S. , Netto, George J. , Fine, Samson W. , Sirohi, Deepika , Kaushal, Seema , Robinson, Brian D. , Kweldam, Charlotte F. , Humphrey, Peter A. , Hansel, Donna E. , Schultz, Luciana , Przybycin, Christopher G. , Mehra, Rohit , Kunju, Lakshmi P., Aron, Manju , Kuroda, Naoto , Tavora, Fabio, Grignon, David J. , Epstein, Jonathan I. , Reuter, Victor E. , Amin, Mahul B. , Távora, Fábio , Robinson, Brian D. , Trpkov, Kiril , Marzo, Angelo M. De , Menon, Santosh , Williamson, Sean R. , Sangoi, Ankur R. , Magi‐Galluzzi, Cristina , Shah, Rajal B. , Kryvenko, Oleksandr N. , Kench, James G. , Kwast, Theodorus van der

Mayo Clinic

American Journal of Surgical Pathology | December 24, 2019 | Volume: 44 | Issue: 5 | Pages: 673-680

10.1097/pas.0000000000001417 | PMID 31876580 Get It

Intraductal carcinoma of the prostate (IDC-P) has been recently recognized by the World Health Organization classification of prostatic tumors as a distinct entity, most often occurring concurrently with invasive prostatic adenocarcinoma (PCa). Whether documented admixed with PCa or in its rare pure form, numerous studies associate this entity with clinical aggressiveness. Despite increasing clinical experience and requirement of IDC-P documentation in protocols for synoptic reporting, the specifics of its potential contribution to assessment of grade group (GG) and cancer quantitation of PCa in both needle biopsies (NBx) and radical prostatectomy (RP) specimens remain unclear. Moreover, there are no standard guidelines for incorporating basal cell marker immunohistochemistry (IHC) in the diagnosis of IDC-P, either alone or as part of a cocktail with AMACR/racemase. An online survey containing 26 questions regarding diagnosis, reporting practices, and IHC resource utilization, focusing on IDC-P, was undertaken by 42 genitourinary subspecialists from 9 countries. The degree of agreement or disagreement regarding approaches to individual questions was classified as significant majority (>75%), majority (51% to 75%), minority (26% to 50%) and significant minority (≤25%). IDC-P with or without invasive cancer is considered a contraindication for active surveillance by the significant majority (95%) of respondents, although a majority (66%) also agreed that the clinical significance/behavior of IDC-P on NBx or RP with PCa required further study. The majority do not upgrade PCa based on comedonecrosis seen only in the intraductal component in NBx (62%) or RP (69%) specimens. Similarly, recognizable IDC-P with GG1 PCa was not a factor in upgrading in NBx (78%) or RP (71%) specimens. The majority (60%) of respondents include readily recognizable IDC-P in assessment of linear extent of PCa at NBx. A significant majority (78%) would use IHC to confirm or exclude intraductal carcinoma if other biopsies showed no PCa, while 60% would use it to confirm IDC-P with invasive PCa in NBx if it would change the overall GG assignment. Nearly half (48%, a minority) would use IHC to confirm IDC-P for accurate Gleason pattern 4 quantitation. A majority (57%) report the percentage of IDC-P when present, in RP specimens. When obvious Gleason pattern 4 or 5 PCa is present in RP or NBx, IHC is rarely to almost never used to confirm the presence of IDC-P by the significant majority (88% and 90%, respectively). Most genitourinary pathologists consider IDC-P to be an adverse prognostic feature independent of the PCa grade, although recommendations for standardization are needed to guide reporting of IDC-P vis a vis tumor quantitation and final GG assessment. The use of IHC varies widely and is performed for a multitude of indications, although it is used most frequently in scenarios where confirmation of IDC-P would impact the GG assigned. Further study and best practices recommendations are needed to provide guidance with regards to the most appropriate indications for IHC use in scenarios regarding IDC-P.
Ovatodiolide Suppresses Oral Cancer Malignancy by Down-Regulating Exosomal Mir-21/STAT3/β-Catenin Cargo and Preventing Oncogenic Transformation of Normal Gingival Fibroblasts
Chen, Jia‐Hong , Wu, Alexander T.H. , Bamodu, Oluwaseun Adebayo , Yadav, Vijesh Kumar , Chao, Tsu-Yi, Tzeng, Yew‐Min , Hsiao, Michael , Lee, Jih-Chin, Wu, Alexander T H , Chen, Jia-Hong , Mukhopadhyay, Debabrata , Lee, Jih‐Chin

Mayo Clinic

Cancers | December 24, 2019 | Volume: 12 | Issue: 1 | Pages: 56

10.3390/cancers12010056 | PMID 31878245 Get It

Oral squamous cell carcinoma (OSCC) is among the most commonly diagnosed malignancies in the world. Patients with OSCC often develop treatment resistance, resulting in a poor prognosis. Mounting evidence indicates that interactions between cancerous cells and other components of the tumor microenvironment (TME) determine their response to treatment. Herein, we examined the role of cancer stem cell-derived extracellular vesicles (CSC_EVs) generated from CAL27 and SCC-15 OSCC cells in the development of cisplatin (CDDP) resistance. We demonstrated that CSC_EVs enhance CDDP resistance, clonogenicity, and the tumorsphere formation potential of OSCC cells. Our bioinformatics analyses revealed that OSCC_EVs are enriched with microRNA (miR)-21-5p and are associated with increased metastasis, stemness, chemoresistance, and poor survival in patients with OSCC. Mechanistically, enhanced activity of CSC_EVs was positively correlated with upregulated β-catenin, phosphatidylinositol-3 kinase (PI3K), signal transducer and activator of transcription 3 (STAT3), mammalian target of rapamycin (mTOR), and transforming growth factor (TGF)-β1 messenger (m)RNA and protein expression levels. CSC_EVs also conferred a cancer-associated fibroblast (CAF) phenotype on normal gingival fibroblasts (NGFs), with the resultant CAFs enhancing the oncogenicity of OSCC cells. Interestingly, treatment with ovatodiolide (OV), the bioactive component of Anisomeles indica, suppressed OSCC tumorigenesis by reducing the cargo content of EVs derived from CSCs, suppressing self-renewal, and inhibiting the NGF-CAF transformation by disrupting EV-TME interactions. Moreover, by suppressing miR-21-5p, STAT3, and mTOR expressions in CSC_EVs, OV re-sensitized CSCs to CDDP and suppressed OSCC tumorigenesis. In vivo, treatment with OV alone or in combination with CDDP significantly reduced the tumor sphere-forming ability and decreased EV cargos containing mTOR, PI3K, STAT3, β-catenin, and miR-21-5p. In summary, our findings provide further strong evidence of OV’s therapeutic effect in OSCC.
1322: A QUALITY IMPROVEMENT INITIATIVE TO IMPROVE ROUNDING IN THE MEDICAL INTENSIVE CARE UNIT
Veerabattini, N., Breighner, Crystal , Frank, Ryan D. , Zhang, Zhenmei , Myers, Melissa A , Niven, Alexander S.

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 638-638

10.1097/01.ccm.0000645204.78670.8a Get It